Syed K Mohsin

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint Biomarker profile and genetic abnormalities in lobular carcinoma in situ
    Syed K Mohsin
    The Breast Center and Department of Pathology, Baylor College of Medicine, One Baylor Plaza MS 600, Houston, TX 77030, USA
    Breast Cancer Res Treat 90:249-56. 2005
  2. ncbi request reprint Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study
    Syed K Mohsin
    The Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    Mod Pathol 17:1545-54. 2004
  3. ncbi request reprint The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice
    Kendall Wu
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 62:6376-80. 2002
  4. ncbi request reprint Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations
    Xiaomei Zhang
    Breast Center, Baylor College of Medicine, One Baylor Plaza, N1210 03, Houston, TX 77030, USA
    Oncogene 24:4220-31. 2005
  5. ncbi request reprint Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
    M Carolina Gutierrez
    Breast Center and Department of Pathology, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 23:2469-76. 2005
  6. ncbi request reprint Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer
    Syed K Mohsin
    Breast Center at Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
    Breast Cancer Res Treat 94:205-11. 2005
  7. ncbi request reprint Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies
    Michelle D Martin
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Breast Cancer Res Treat 95:7-12. 2006
  8. pmc Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer
    Sangjun Lee
    Breast Center, Baylor College of Medicine, Houston, Texas, USA
    Breast Cancer Res 8:R6. 2006
  9. ncbi request reprint Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors
    Chunhua Lu
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 95:1825-33. 2003
  10. pmc Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer
    Ilenia Migliaccio
    Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600, Room N1110, Houston, TX 77030, USA
    Breast Cancer Res Treat 123:651-60. 2010

Collaborators

Detail Information

Publications25

  1. ncbi request reprint Biomarker profile and genetic abnormalities in lobular carcinoma in situ
    Syed K Mohsin
    The Breast Center and Department of Pathology, Baylor College of Medicine, One Baylor Plaza MS 600, Houston, TX 77030, USA
    Breast Cancer Res Treat 90:249-56. 2005
    ..Our findings suggest that five known prognostic factors in IBC do not have prognostic utility in LCIS. Multiple genetic mechanisms may be involved in the development of LCIS...
  2. ncbi request reprint Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study
    Syed K Mohsin
    The Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    Mod Pathol 17:1545-54. 2004
    ..Progesterone receptor assessed by immunohistochemistry provides useful information about clinical outcome and it is better than progesterone receptor measured by ligand-binding assay...
  3. ncbi request reprint The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice
    Kendall Wu
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 62:6376-80. 2002
    ..These studies suggest that receptor-selective retinoids are promising agents for the prevention of breast cancer and that they may be particularly useful in preventing ER-negative breast cancer...
  4. ncbi request reprint Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations
    Xiaomei Zhang
    Breast Center, Baylor College of Medicine, One Baylor Plaza, N1210 03, Houston, TX 77030, USA
    Oncogene 24:4220-31. 2005
    ..This is a first report of a mouse model of antiestrogen-resistant ER-positive breast cancers, and could provide a powerful tool to study the molecular mechanisms that control antiestrogen resistance...
  5. ncbi request reprint Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
    M Carolina Gutierrez
    Breast Center and Department of Pathology, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 23:2469-76. 2005
    ..To evaluate growth factor receptor cross talk with the estrogen receptor (ER) in paired clinical breast cancer specimens and in a xenograft model before tamoxifen and at tumor progression as a possible mechanism for tamoxifen resistance...
  6. ncbi request reprint Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer
    Syed K Mohsin
    Breast Center at Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
    Breast Cancer Res Treat 94:205-11. 2005
    ..Proliferation, determined by Ki67 staining, was not significantly changed. Clinical trials of this type are difficult to carry out and modifications in trial design are needed to make this process more efficient...
  7. ncbi request reprint Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies
    Michelle D Martin
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Breast Cancer Res Treat 95:7-12. 2006
    ..Tamoxifen and/or anthracylcene-based chemotherapies eliminated all MTA1 associations with clinical outcome, suggesting MTA1 overexpression predicts early disease relapse, but sensitizes breast tumors to systemic therapies...
  8. pmc Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer
    Sangjun Lee
    Breast Center, Baylor College of Medicine, Houston, Texas, USA
    Breast Cancer Res 8:R6. 2006
    ....
  9. ncbi request reprint Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors
    Chunhua Lu
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 95:1825-33. 2003
    ..We examined whether ZD1839 blocks signal transduction and prevents the development of ER-negative breast cancer...
  10. pmc Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer
    Ilenia Migliaccio
    Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600, Room N1110, Houston, TX 77030, USA
    Breast Cancer Res Treat 123:651-60. 2010
    ..0001) when compared with patients with PR-/IRS-1- tumors. In conclusion, nuclear IRS-1 may be a useful marker to predict tamoxifen response in patients with early breast cancer, particularly when assessed in combination with PR...
  11. ncbi request reprint Neoadjuvant trastuzumab induces apoptosis in primary breast cancers
    Syed K Mohsin
    Breast Center at Baylor College of Medicine The Methodist Hospital, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
    J Clin Oncol 23:2460-8. 2005
    ..Greater understanding of the cellular response in trastuzumab-treated patients will provide insight into the clinical management of patients...
  12. ncbi request reprint Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance
    Rachel Schiff
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 10:331S-6S. 2004
    ..We will also emphasize open questions and future challenges in the dynamic research field of molecular ER biology from the endocrine therapy perspective...
  13. ncbi request reprint Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters
    Suzanne A W Fuqua
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 63:2434-9. 2003
    ..These results suggest that ERbeta expression is not a surrogate for ERalpha in clinical breast tumors and, as such, could be a useful biomarker in its own right...
  14. ncbi request reprint Maspin expression in invasive breast cancer: association with other prognostic factors
    Syed K Mohsin
    Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    J Pathol 199:432-5. 2003
    ..Additional studies are needed to evaluate further this expression profile of maspin in breast cancer...
  15. ncbi request reprint Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069
    Kendall Wu
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 11:467-74. 2002
    ....
  16. doi request reprint Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution
    D Craig Allred
    Department of Pathology, Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Cancer Res 14:370-8. 2008
    ..Human invasive breast cancers (IBC) show enormous histologic and biological diversity. This study comprehensively evaluated diversity in ductal carcinoma in situ (DCIS), the immediate precursors of IBCs...
  17. pmc Alterations of gene expression in the development of early hyperplastic precursors of breast cancer
    Sangjun Lee
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Pathol 171:252-62. 2007
    ..Because HELUs are such early potential precursors of breast cancer, targeting some of these alterations may be especially promising strategies for breast cancer prevention...
  18. ncbi request reprint Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer
    Suleiman Massarweh
    Department of Internal Medicine and Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
    Cancer Res 66:8266-73. 2006
    ..Combining endocrine therapy with EGFR/HER-2/neu inhibitors should be tested in clinical breast cancer, but a more complete blockade of EGFR/HER-2/neu may be optimal...
  19. ncbi request reprint Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer
    Richard R Love
    University of Wisconsin Comprehensive Cancer Center, 610 Walnut Street, Madison, WI 53705 2397, USA
    J Clin Oncol 20:2559-66. 2002
    ..Approximately 350,000 new cases of breast cancer are diagnosed annually in premenopausal Asian women who have lower levels of estrogen than western women...
  20. ncbi request reprint Colonic adenocarcinoma metastatic to the urinary tract versus primary tumors of the urinary tract with glandular differentiation: a report of 7 cases and investigation using a limited immunohistochemical panel
    Pheroze Tamboli
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Arch Pathol Lab Med 126:1057-63. 2002
    ....
  21. ncbi request reprint Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer
    Richard R Love
    Departments of Medicine and Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI 53726, USA
    J Clin Oncol 21:453-7. 2003
    ....
  22. ncbi request reprint Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women
    Hazel B Nichols
    University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA
    Cancer Epidemiol Biomarkers Prev 14:41-7. 2005
    ..Our findings support the hypothesis that some breast cancer risk factors differ by ER and HER-2/neu tumor marker subtypes...
  23. ncbi request reprint Decreased expression of e6-associated protein in breast and prostate carcinomas
    Xiuhua Gao
    Cancer Center, Criss III, Room 352, Creighton University, 2500 California Plaza, Omaha, Nebraska 68178, USA
    Endocrinology 146:1707-12. 2005
    ....
  24. ncbi request reprint Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast
    Frances P O'Malley
    Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada
    Mod Pathol 19:172-9. 2006
    ..1-97.4%), than for determining its presence (90.4%: 95% CI, 79.9-96.7%). We conclude that the diagnosis of FEA and its distinction from CCLs without atypia is highly reproducible with the use of available diagnostic criteria...
  25. ncbi request reprint ER expression is not bimodal in breast cancer
    D Craig Allred
    Am J Clin Pathol 124:474-5; author reply 475-6. 2005